anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Ruxolitinib
Trial phase: Phase 2
ATC code: D11AH09 | L01EJ01 | L01XE18
SMILES: N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 38
Group description: Participants received CTP-543 8 mg tablets, twice daily for up to 24 weeks.
Eligibility criteria:
Inclusion Criteria:

Definitive diagnosis of alopecia areata with a current episode lasting at least 6 months and not exceeding 10 years at the time of Screening. Total disease duration greater than 10 years is permitted.
At least 50% scalp hair loss, as defined by a Severity of Alopecia Tool (SALT) score ≥50, at Screening and Baseline.
Clinical lab results within the normal range

Exclusion Criteria:

Active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical treatment to the scalp, significant trauma to the scalp, or untreated actinic keratosis on the scalp.
Treatment with systemic immunosuppressive medications or biologics.
Vaccination with herpes zoster vaccine or any live virus within 6 weeks of screening or during the study
Intervention: Ruxolitinib
Trial phase: Phase 2
ATC code: D11AH09 | L01EJ01 | L01XE18
SMILES: N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 36
Group description: Participants received CTP-543 12 mg tablets, twice daily for up to 24 weeks.
Eligibility criteria:
Inclusion Criteria:

Definitive diagnosis of alopecia areata with a current episode lasting at least 6 months and not exceeding 10 years at the time of Screening. Total disease duration greater than 10 years is permitted.
At least 50% scalp hair loss, as defined by a Severity of Alopecia Tool (SALT) score ≥50, at Screening and Baseline.
Clinical lab results within the normal range

Exclusion Criteria:

Active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical treatment to the scalp, significant trauma to the scalp, or untreated actinic keratosis on the scalp.
Treatment with systemic immunosuppressive medications or biologics.
Vaccination with herpes zoster vaccine or any live virus within 6 weeks of screening or during the study
Intervention: OXYTOCIN
Trial phase: Phase 3
ATC code: H01BB02
SMILES: CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 90
Group description: Multiparous women will begin cervical ripening with a cervical ripening balloon alone. After the balloon is expelled or removed, induction of labor will proceed with pitocin per standard protocol at MacDonald Women's Hospital.

Oxytocin
Eligibility criteria:
Inclusion Criteria:

Age > 18 years
Gestational age > 34 + 0/7 weeks
Prior spontaneous vaginal delivery
Clinical or U/S EFW of <4500 grams
Singleton gestation
Cervical dilation <2 cm

Exclusion Criteria:

Any contraindication to cervical ripening balloon, pitocin, or vaginal delivery
Placenta within 2 cm of cervical os
Placental abruption, chorioamninoitis, or systemic infection prior to induction
Rupture of membranes prior to induction ->1 prior C/S
Intervention: OXYTOCIN
Trial phase: Phase 3
ATC code: H01BB02
SMILES: CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 90
Group description: Multiparous women will begin cervical ripening with a cervical ripening balloon and simultaneous oxytocin. After the balloon is expelled or removed, induction of labor will proceed with pitocin per standard protocol at MacDonald Women's Hospital.

Oxytocin
Eligibility criteria:
Inclusion Criteria:

Age > 18 years
Gestational age > 34 + 0/7 weeks
Prior spontaneous vaginal delivery
Clinical or U/S EFW of <4500 grams
Singleton gestation
Cervical dilation <2 cm

Exclusion Criteria:

Any contraindication to cervical ripening balloon, pitocin, or vaginal delivery
Placenta within 2 cm of cervical os
Placental abruption, chorioamninoitis, or systemic infection prior to induction
Rupture of membranes prior to induction ->1 prior C/S
Intervention: Daptomycin
Trial phase: Phase 3
ATC code: J01XX09
SMILES: CCCCCCCCCC(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(N)=O)C(=O)NC(CC(=O)O)C(=O)NC1C(=O)NCC(=O)NC(CCCN)C(=O)NC(CC(=O)O)C(=O)NC(C)C(=O)NC(CC(=O)O)C(=O)NCC(=O)NC(CO)C(=O)NC(C(C)CC(=O)O)C(=O)NC(CC(=O)c2ccccc2N)C(=O)OC1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 198
Group description: Daptomycin 6 mg/kg, with or without aztreonam

Daptomycin: Daptomycin 6 mg/kg (up to 10 mg/kg based on institutional standards) as a 0.5 h infusion, with or without aztreonam
Eligibility criteria:
Inclusion Criteria:

Male or female ≥ 18 years of age
Staphylococcus aureus bacteremia (SAB), based on at least one positive blood culture obtained within the 72 h prior to randomization

At least one of the following signs or symptoms of bacteremia:

fever (e.g.≥ 38 °C/100.4 °F measured orally)
white blood cell count > 10,000 or < 4,000 cells/µL, or > 10% immature neutrophils (bands)
tachycardia (heart rate > 90 bpm)
hypotension (systolic blood pressure < 90 mmHg)

At least one of the following:

SAB in patients undergoing chronic intermittent hemodialysis or peritoneal dialysis
Persistent SAB
Definite native-valve right-sided infective endocarditis by Modified Duke's Criteria
Other forms of complicated SAB
Osteomyelitis (including vertebral, sternal, or long-bone osteomyelitis)
Epidural or cerebral abscess
Other inclusion criteria have been applied

Exclusion Criteria:

Treatment with potentially effective (anti-staphylococcal) systemic antibacterial treatment for more than 48 h within the 7 days prior to randomization; Exception: Documented failure of bloodstream clearance
Bloodstream or non-bloodstream concomitant infections with Gram-negative bacteria that are known to be non-susceptible to either ceftobiprole or aztreonam
Left-sided infective endocarditis
Prosthetic cardiac valves or valve support rings, cardiac pacemakers, automatic implantable cardioverter-defibrillator, or left-ventricular assist devices
Community- or hospital-acquired pneumonia
Opportunistic infections within 30 days prior to randomization, where the underlying cause of these infections is still active
Requirement for continuous renal-replacement therapy
Women who are pregnant or nursing
Other exclusion criteria have been applied
Intervention: OXYTOCIN
Trial phase: Phase 4
ATC code: H01BB02
SMILES: CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 140
Group description: 1) Control group: Lean cohort: BMI ≤25, at <20 weeks gestation or BMI ≤28 at a term gestation, low dose oxytocin protocol

Low dose oxytocin regimen (the standard at Banner University Labor and Delivery, as well as across the United States): 30 units in 500cc 0.9% normal saline bag (60 milliunit/cc). Starting rate would be 2 milliunit/minute, or 2cc/hour. The medication will be increased by 2 milliunit/minute = 2cc/hr every 30 minutes until adequacy of contraction or cervical change. At 20 milliunit/minute = 20cc/hr, provider will assess patient for eligibility to continue to increase oxytocin dosage.

Time frame measured from start of oxytocin infusion until the mother is discharged from hospital after giving birth.
Eligibility criteria:
Inclusion Criteria:

Singleton pregnancy ≥ 37 weeks gestation
Patient presented for induction of labor who is determined to be a candidate for oxytocin
Cephalic presentation
Reassuring fetal health assessment (no abnormal findings in fetal assessment, see below)
Meeting one of the following BMI category:

Obese group: BMI ≥30 at <20 weeks of pregnancy, or BMI ≥35 at a term gestation of pregnancy Lean group: BMI ≤25 at <20 weeks of pregnancy, or BMI ≤28 at a term gestation of pregnancy

Exclusion Criteria:

Non-reassuring fetal assessment at the time of recruitment
Previous cervical ripening agents (cytotec, cervidil, cervical Foley Balloon)
<18 years of age
Prisoners
Any patients contraindicated for vaginal delivery
Multiple gestations
History of previous cesarean delivery
Patients with history of significant cardiac disease
Fetal demise
Estimated fetal weight greater than 4500 grams in diabetic and 5000 grams in non-diabetic mother
Ruptured membranes
Spontaneous labor (latent or active phase)
Augmentation of labor (latent or active phase)
Intervention: OXYTOCIN
Trial phase: Phase 4
ATC code: H01BB02
SMILES: CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 140
Group description: 2) Intervention group: Lean cohort: BMI ≤25, at <20 weeks gestation or BMI ≤28 at a term gestation, high dose oxytocin protocol

High dose oxytocin regimen (endorsed by American College of Obstetricians and Gynecologists): 90 units in 500cc 0.9% normal saline bag (180 milliunit/cc). Starting rate would be 6 milliunit/minute, or 2cc/hour. The medication will be increased by 6 milliunit/minute = 2cc/hr every 30 minutes until adequacy of contraction or cervical change. At 60 milliunit/minute = 20cc/hr, provider will assess patient for eligibility to continue to increase oxytocin dosage.

Time frame measured from start of oxytocin infusion until the mother is discharged from hospital after giving birth.
Eligibility criteria:
Inclusion Criteria:

Singleton pregnancy ≥ 37 weeks gestation
Patient presented for induction of labor who is determined to be a candidate for oxytocin
Cephalic presentation
Reassuring fetal health assessment (no abnormal findings in fetal assessment, see below)
Meeting one of the following BMI category:

Obese group: BMI ≥30 at <20 weeks of pregnancy, or BMI ≥35 at a term gestation of pregnancy Lean group: BMI ≤25 at <20 weeks of pregnancy, or BMI ≤28 at a term gestation of pregnancy

Exclusion Criteria:

Non-reassuring fetal assessment at the time of recruitment
Previous cervical ripening agents (cytotec, cervidil, cervical Foley Balloon)
<18 years of age
Prisoners
Any patients contraindicated for vaginal delivery
Multiple gestations
History of previous cesarean delivery
Patients with history of significant cardiac disease
Fetal demise
Estimated fetal weight greater than 4500 grams in diabetic and 5000 grams in non-diabetic mother
Ruptured membranes
Spontaneous labor (latent or active phase)
Augmentation of labor (latent or active phase)
Intervention: OXYTOCIN
Trial phase: Phase 4
ATC code: H01BB02
SMILES: CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 140
Group description: 3) Control group: Obese cohort: BMI ≥30, at <20 weeks gestation or BMI ≥35 at a term gestation, low dose oxytocin protocol

Low dose oxytocin regimen (the standard at Banner University Labor and Delivery, as well as across the United States): 30 units in 500cc 0.9% normal saline bag (60 milliunit/cc). Starting rate would be 2 milliunit/minute, or 2cc/hour. The medication will be increased by 2 milliunit/minute = 2cc/hr every 30 minutes until adequacy of contraction or cervical change. At 20 milliunit/minute = 20cc/hr, provider will assess patient for eligibility to continue to increase oxytocin dosage.

Time frame measured from start of oxytocin infusion until the mother is discharged from hospital after giving birth.
Eligibility criteria:
Inclusion Criteria:

Singleton pregnancy ≥ 37 weeks gestation
Patient presented for induction of labor who is determined to be a candidate for oxytocin
Cephalic presentation
Reassuring fetal health assessment (no abnormal findings in fetal assessment, see below)
Meeting one of the following BMI category:

Obese group: BMI ≥30 at <20 weeks of pregnancy, or BMI ≥35 at a term gestation of pregnancy Lean group: BMI ≤25 at <20 weeks of pregnancy, or BMI ≤28 at a term gestation of pregnancy

Exclusion Criteria:

Non-reassuring fetal assessment at the time of recruitment
Previous cervical ripening agents (cytotec, cervidil, cervical Foley Balloon)
<18 years of age
Prisoners
Any patients contraindicated for vaginal delivery
Multiple gestations
History of previous cesarean delivery
Patients with history of significant cardiac disease
Fetal demise
Estimated fetal weight greater than 4500 grams in diabetic and 5000 grams in non-diabetic mother
Ruptured membranes
Spontaneous labor (latent or active phase)
Augmentation of labor (latent or active phase)
Intervention: OXYTOCIN
Trial phase: Phase 4
ATC code: H01BB02
SMILES: CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 140
Group description: 4) Intervention group: Obese cohort: BMI ≥30, at <20 weeks gestation or BMI ≥35 at a term gestation, high dose oxytocin protocol

High dose oxytocin regimen (endorsed by American College of Obstetricians and Gynecologists): 90 units in 500cc 0.9% normal saline bag (180 milliunit/cc). Starting rate would be 6 milliunit/minute, or 2cc/hour. The medication will be increased by 6 milliunit/minute = 2cc/hr every 30 minutes until adequacy of contraction or cervical change. At 60 milliunit/minute = 20cc/hr, provider will assess patient for eligibility to continue to increase oxytocin dosage.

Time frame measured from start of oxytocin infusion until the mother is discharged from hospital after giving birth.
Eligibility criteria:
Inclusion Criteria:

Singleton pregnancy ≥ 37 weeks gestation
Patient presented for induction of labor who is determined to be a candidate for oxytocin
Cephalic presentation
Reassuring fetal health assessment (no abnormal findings in fetal assessment, see below)
Meeting one of the following BMI category:

Obese group: BMI ≥30 at <20 weeks of pregnancy, or BMI ≥35 at a term gestation of pregnancy Lean group: BMI ≤25 at <20 weeks of pregnancy, or BMI ≤28 at a term gestation of pregnancy

Exclusion Criteria:

Non-reassuring fetal assessment at the time of recruitment
Previous cervical ripening agents (cytotec, cervidil, cervical Foley Balloon)
<18 years of age
Prisoners
Any patients contraindicated for vaginal delivery
Multiple gestations
History of previous cesarean delivery
Patients with history of significant cardiac disease
Fetal demise
Estimated fetal weight greater than 4500 grams in diabetic and 5000 grams in non-diabetic mother
Ruptured membranes
Spontaneous labor (latent or active phase)
Augmentation of labor (latent or active phase)
Intervention: Vadadustat
Trial phase: Phase 2
ATC code: B03XA08
SMILES: O=C(O)CNC(=O)c1ncc(-c2cccc(Cl)c2)cc1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 2
Group description: Participants were to discontinue epoetin alfa, administered during the 28-day Screening Period, and initiate vadadustat on Day 1 of the 20-week treatment period. The vadadustat daily oral dose was adjustable based on the target hemoglobin (Hb) level of 10.0 to 11.0 grams per deciliter (g/dL).
Eligibility criteria:
Inclusion Criteria:

Male and female subjects ≥18 years of age
Receiving chronic maintenance hemodialysis for end-stage kidney disease
Currently receiving epoetin alfa for anemia
Hb between 8.5 and 10.0 g/dL during screening

Exclusion Criteria:

Anemia due to a cause other than CKD or presence of active bleeding or recent blood loss
Sickle cell disease, myelodysplastic syndromes, bone marrow fibrosis, hematologic malignancy, myeloma, hemolytic anemia, thalassemia, or pure red cell aplasia
Red blood cell transfusion within 4 weeks prior to or during screening
Anticipated to recover adequate kidney function to no longer require hemodialysis during study participation
Intervention: rhEPO
Trial phase: Phase 2
SMILES: COC1C(O)CC(=O)OC(C)CC=CC=CC(OC2CC(C)(O)C(O)C(C)O2)C(C)CC(CCO)C1OC1OC(C)C(OC2CC(C)(O)C(O)C(C)O2)C(N(C)C)C1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 2
Group description: Participants were to receive the same dose of epoetin alfa administered during the 28-day Screening Period starting on Day 1 of the 20-week Treatment Period. Epoetin alfa was administered based on the approved label for adult participants with Chronic Kidney Disease (CKD) on dialysis, and the dose was adjustable based on Hb level, as clinically indicated throughout the study.
Eligibility criteria:
Inclusion Criteria:

Male and female subjects ≥18 years of age
Receiving chronic maintenance hemodialysis for end-stage kidney disease
Currently receiving epoetin alfa for anemia
Hb between 8.5 and 10.0 g/dL during screening

Exclusion Criteria:

Anemia due to a cause other than CKD or presence of active bleeding or recent blood loss
Sickle cell disease, myelodysplastic syndromes, bone marrow fibrosis, hematologic malignancy, myeloma, hemolytic anemia, thalassemia, or pure red cell aplasia
Red blood cell transfusion within 4 weeks prior to or during screening
Anticipated to recover adequate kidney function to no longer require hemodialysis during study participation
Intervention: 1-(1-Methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl 4-cyclobutylpiperazine-1-carboxylate
Trial phase: Phase 2
SMILES: Cn1nc(N2CCC(OC(=O)N3CCN(C4CCC4)CC3)CC2)ccc1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 21
Group description: LML134 5mg
Eligibility criteria:
Inclusion Criteria:

Male and female subjects 18 to 65 years of age included.
Confirmed diagnosis of SWD according to ICSD-3 criteria at Screening.
Subjects who are at least moderately ill with respect to sleepiness on work nights, including commute to and from work, as assessed by the Clinical Global Impression-Severity scale (CGI-S, score ≥4) at Screening.
Subjects must work 5 or more night shifts per month, and 2 or more shifts must occur on consecutive nights, with 6 or more hours worked between 10 pm and 8 am, as confirmed by subject at Screening.
Subjects must have mean sleep latency ≤8 minutes on nighttime MSLT at Screening.
Subjects must weigh at least 50 kg at Screening to participate in the study, and must have a body mass index (BMI) within the range of 18 - 35 kg/m2. BMI = Body weight (kg) / [Height (m)]2

Exclusion Criteria:

Women of child-bearing potential (defined as all women physiologically capable of becoming pregnant) unless they are using highly effective methods of contraception from start of taking the study medication in the first period until stopping the medication in the second treatment period and for 3 additional days after AND an additional barrier method of contraception will be used while taking the study medication and for 3 additional days in both treatment periods.
Sexually active males unwilling to use a condom during intercourse while taking investigational drug and for 3 days after stopping investigational drug. A condom is required for all sexually active male participants to prevent them from fathering a child AND to prevent delivery of the investigational drug via seminal fluid to their partner.
Heavy smokers who smoke more than 10 cigarettes a day and occasional or light smokers (not more than 10 cigarettes per day) who are not willing to, or in their own or the investigators opinion are not able to refrain from tobacco/nicotine use for at least 12 hours without nicotine craving or other withdrawal symptoms
Subjects for whom it is not safe to discontinue or who are unwilling to discontinue use of modafinil, hypnotics, and antihistamines for the periods specified in the prohibited medication section.
Heavy caffeine consumers, i.e. subjects who consume greater than 850 mg of caffeine per day (approximate equivalent of three tall cups of Starbucks coffee) in coffee, tea, or other caffeine-containing drinks.
Subjects who have high risk of obstructive sleep apnea, indicated by score of 5 or more on the STOP-BANG questionnaire.
Presence of any sleep disorder other than SWD, as confirmed by PSG at screening.
Intervention: SULFUR HEXAFLUORIDE
Trial phase: Phase 1 | Phase 2
ATC code: V08DA05
SMILES: FS(F)(F)(F)(F)F
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 74
Group description: All subjects will have an abdominal non-contrast ultrasound performed. Lumason will then be administered at a dose of 0.03mL/kg up to a maximum dose of 2.4mL and a contrast-enhanced ultrasound will be performed. The dose will be given twice, for a total maximum dose per subject of 4.8mL

Lumason: Lumason will be administered at a dose of 0.03 mL/kg up to a maximum dose of 2.4mL injected into a peripheral intravenous catheter. An abdominal contrast enhanced ultrasound will be performed to look for solid organ injury. The will be given twice during the intervention, for a total maximum dose per subject of 4.8mL.
Eligibility criteria:
Inclusion Criteria:

Hemodynamically stable, as determined by the trauma team
Age 8 through 17 years
Interpretable CT of the abdomen and pelvis that demonstrates at least one abdominal solid organ injury among the liver, spleen, pancreas, and kidneys
Plan for observation or admission to the hospital
Candidate for abdominal ultrasound based on body habitus
Have a Glasgow Coma Score of 15
Able to complete the study procedures within 48 hours of injury

Exclusion Criteria:

Known cardiac abnormality
Pulmonary hypertension
Known sensitivity to sulfur hexafluoride, polyethylene glycol 4000, distearoylphosphatidylcholine (DSPC), dipalmitoylphosphatidylglycerol sodium (DPPG-Na), or palmitic acid
Unable to roll over
Unable to assent
Pregnant
Lactating
CT images not available for transmission to central image repository
Intervention: ASCORBIC ACID
Trial phase: Phase 2
ATC code: A11GA01 | A11GB01 | B03AA10 | G01AD03 | S01XA15
SMILES: O=C1OC(C(O)CO)C(O)=C1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 10
Group description: Vitamin C: 200mg/kg/day split into 4 doses infused every six hours over 30 minutes in 50ml D5W
Eligibility criteria:
Inclusion Criteria:

Age >/= 21 years
Diagnosis of atrial fibrillation with plans for a catheter-based ablation procedure
Ability to provide informed consent and willingness to be included in the study

Exclusion Criteria:

Known allergy to Vitamin C
Inability to obtain informed consent
Diabetes mellitus either requiring the use of insulin therapy or not requiring the use of insulin therapy but which is uncontrolled, defined as a glycosylated hemoglobin of greater than or equal to 8%
Prior catheter-based ablation for atrial fibrillation
Pregnancy or breast feeding
Active renal calculus
Active acute or chronic infection (including HIV or hepatitis C)
Active or recent (within 5 years) malignancy
Autoimmune or autoinflammatory disease
Recent or active use of immunosuppressive medications
Non-English speaking
Ward of the state (inmate, other)